Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
David M. Ross(Flinders Medical Centre), Timothy P. Hughes(Royal Adelaide Hospital), Christopher Arthur(Royal North Shore Hospital), Deborah L. White(ANZCHOG), Cassandra Slader(Novartis (Australia)), Anthony K. Mills(Princess Alexandra Hospital), Jarrad M. Goyne(South Australia Pathology), John F. Seymour(The Royal Melbourne Hospital), Andrew Grigg(The Royal Melbourne Hospital), Anthony P. Schwarer(The Alfred Hospital), Junia V. Melo(The University of Adelaide), Robin Filshie(St Vincent's Hospital Melbourne), David T Yeung(Royal Adelaide Hospital), Phuong Dang(South Australia Pathology), Susan Branford(South Australia Pathology)
Cited by 705
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k